RPS6KB1 and cancer: Clinical research investigations have already developed promising and pharmacologically available p70S6K1 small molecule inhibitors namely, LY2584702 [59], DG2 [60] and AT7867 [61] which have impressive pre-clinical data for efficacy and safety for the treatment of cancer [62].